Northstar Advisory Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY.RT
JCI
BC
TNB
WAM
IAIM
Northstar Advisory Group's BMY.RT Position: Q1 2021 in Review
Northstar Advisory Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 67,005 shares — an estimated $46K sold.
Northstar Advisory Group first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $46K in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.
- Northstar Advisory Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
- Northstar Advisory Group sold 67,005 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $46K.
- Northstar Advisory Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
- Northstar Advisory Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $46K in Q4 2020.
- 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.
Based on Northstar Advisory Group's 13F filing for Q1 2021, filed 26 Apr 2021.